Boehringer Ingelheim Enrolls 1st Patient in ‘Real World’ Study of Pradaxa for Deep Vein Thrombosis and PE
News, Pulmonary embolism
Boehringer Ingelheim pharmaceutical company recently announced the launch and enrollment of the first patient in its RE-COVERY DVT/PE global observational study, which will eventually include 14,000 patients globally and collect data on ... Read more